KALA Bio Secures $10.75 Million in New Funding
KALA BIO, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on advancing treatments for eye diseases, has successfully raised $10.75 million through a private placement. This funding comes through the sale of 1,340,603 common shares at $6.44 each and 3,286 Series I preferred shares at $644.00 each. The closing of this transaction is slated for approximately the end of a specified fiscal period, contingent upon customary conditions being met. With a current market valuation near $32 million, KALA's stock has seen a recent increase exceeding 16% in just a week.
The Significance of the Funding
This financial boost is particularly critical as KALA BIO works diligently to develop treatments for rare and severe eye conditions. The company has articulated that these funds will extend its operational runway well into the early part of a future fiscal year. Specifically, they plan to use the proceeds to further advance their lead clinical candidate, KPI-012, which targets persistent corneal epithelial defect (PCED), along with general corporate purposes to ensure the company's ongoing viability and growth.
Clinical Trials Progress
KALA BIO is actively enrolling participants in the Phase 2b CHASE trial for KPI-012 across more than 40 clinical sites. The CEO of the company, Mark Iwicki, has expressed gratitude for the support from investors during this pivotal time, noting that over 80% of the CHASE trial enrollment has already been achieved. Anticipation builds as the company expects to share topline data from this trial by the second quarter of a specified future year, potentially progressing towards Biologics License Application (BLA) submissions.
Financial Health and Future Prospects
The securities involved in this private placement are unregistered under the Securities Act of 1933 and come with restrictions on their resale. However, KALA BIO has committed to registering these securities for resale within 30 days following the placement’s closure. The company's investigational therapies are derived from their proprietary mesenchymal stem cell secretome (MSC-S) platform, offering potential beyond PCED to address Limbal Stem Cell Deficiency and investigate treatments for retinal degenerative diseases.
Market Position and Stock Resilience
Despite facing challenges in achieving profitability, KALA BIO demonstrates promise with an overall financial health score of 'FAIR.' The company has exhibited remarkable resilience, with its stock often reacting contrary to broader market trends, highlighted by a beta of -2.14. This fortitude is critical as the company presses forward with its mission to innovate within the oft-overlooked landscape of ocular pathologies. KPI-012 has already received Orphan Drug and Fast Track designations from the U.S. FDA, underscoring its potential impact.
Recent Developments in the Industry
In related news, another entity in the field, Kala Pharmaceuticals (NASDAQ:KALA), recently disclosed a net loss of $9.0 million for the prior quarter, which fell short of the anticipated $10.0 million loss forecasted by experts. The firm continues to maintain a Buy rating and a target price of $15.00 for its stock. As with KALA BIO, Kala Pharmaceuticals is also advancing its KP-012 drug through the Phase 2b CHASE trial, with significant developments anticipated soon.
KPI-012, which is established on the innovative MSC-S technology, is aimed at addressing the multifaceted nature of PCED—a condition currently lacking an FDA-approved treatment addressing the full spectrum of underlying causes. Additionally, the company is keenly exploring KPI-012's capabilities in treating other ocular deficiencies and conditions. The other candidate in their pipeline, KPI-014, is presently in preclinical stages for inherited retinal degenerative disorders.
Leadership Changes and Future Strategy
In a notable shift, KALA Pharmaceuticals announced the resignation of board member Mark S. Blumenkranz, M.D., from both the board and its committees, with no immediate successor appointed. Furthermore, the company has entered into a private placement agreement led by SR One and ADAR1 Capital Management, successfully raising around $12.5 million to support the ongoing clinical ambitions for KPI-012.
Frequently Asked Questions
What is the primary purpose of KALA BIO's latest funding?
The funding is aimed at advancing clinical development for KPI-012, which is targeting persistent corneal epithelial defect (PCED), as well as general operational needs.
Which clinical trial is KALA BIO currently conducting?
KALA BIO is conducting the Phase 2b CHASE trial for its lead candidate, KPI-012, across multiple clinical sites.
How has KALA BIO's stock performed recently?
Recently, KALA BIO's stock has surged over 16% in just one week, reflecting positive market responses to its financial and clinical developments.
What designations has KPI-012 received?
KPI-012 has received both Orphan Drug and Fast Track designations from the U.S. FDA, highlighting its potential as a significant therapeutic option.
What other candidates is KALA BIO exploring?
In addition to KPI-012, KALA BIO is investigating the potential of KPI-014 for inherited retinal degenerative diseases.
